Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nivolumab plus ipilimumab produced objective responses in patients with advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus ipilimumab with sunitinib for previously untreated clear-cell advanced renal-cell carcinoma. METHODS: We randomly assigned adults in a 1:1 ratio to receive either nivolumab (3 mg per kilogram of body weight) plus ipilimumab (1 mg per kilogram) intravenously every 3 weeks for four doses, followed by nivolumab (3 mg per kilogram) every 2 weeks, or sunitinib (50 mg) orally once daily for 4 weeks (6-week cycle). The coprimary end points were overall survival (alpha level, 0.04), objective response rate (alpha level, 0.001), and progression-free survival (alpha level, 0.009) among patients with intermediate or poor prognostic risk. RESULTS: A total of 1096 patients were assigned to receive nivolumab plus ipilimumab (550 patients) or sunitinib (546 patients); 425 and 422, respectively, had intermediate or poor risk. At a median follow-up of 25.2 months in intermediate- and poor-risk patients, the 18-month overall survival rate was 75% (95% confidence interval [CI], 70 to 78) with nivolumab plus ipilimumab and 60% (95% CI, 55 to 65) with sunitinib; the median overall survival was not reached with nivolumab plus ipilimumab versus 26.0 months with sunitinib (hazard ratio for death, 0.63; P<0.001). The objective response rate was 42% versus 27% (P<0.001), and the complete response rate was 9% versus 1%. The median progression-free survival was 11.6 months and 8.4 months, respectively (hazard ratio for disease progression or death, 0.82; P=0.03, not significant per the prespecified 0.009 threshold). Treatment-related adverse events occurred in 509 of 547 patients (93%) in the nivolumab-plus-ipilimumab group and 521 of 535 patients (97%) in the sunitinib group; grade 3 or 4 events occurred in 250 patients (46%) and 335 patients (63%), respectively. Treatment-related adverse events leading to discontinuation occurred in 22% and 12% of the patients in the respective groups. CONCLUSIONS: Overall survival and objective response rates were significantly higher with nivolumab plus ipilimumab than with sunitinib among intermediate- and poor-risk patients with previously untreated advanced renal-cell carcinoma. (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; CheckMate 214 ClinicalTrials.gov number, NCT02231749 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Third, many of these studies utilized ICIs as monotherapy in a heavily pretreated population whereas current standard first-line therapy often includes a combination of ICIs or ICI with chemotherapy for multiple tumor types (35–40).”
From A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors (2021) · cites this paper as [40]
Experimental — accuracy not yet measuredIn the citing paper
“In that study, patients were randomized either to that regimen or to sunitinib (a VEGF inhibitor); significant prolongation of PFS and overall survival was observed, with 42% of patients achieving a response (many of these durable)11,12.”
From Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial (2022) · cites this paper as [11]
In the citing paper
“Anti-PD-1/PD-L1 agents pared with chemotherapy have also improved response rates and survival in many diseases including lung cancer, triple negative breast cancer, head and neck squamous cell carcinoma, and others.12–14”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationCombined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807 · cited 1×
“Bone§ 95 (22) 97 (23) 112 (20) 119 (22)”
Self-citationSunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,775 · cited 1×
“Diarrhea 145 (27) 21 (4) 278 (52) 28 (5)”
Self-citationNivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519 · cited 4×
“Female 111 (26) 121 (29) 137 (25) 151 (28)”
InfluentialTHE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
CLOPPER, C. J., & PEARSON, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,003 · cited 1×
“Bone§ 95 (22) 97 (23) 112 (20) 119 (22)”
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230 · cited 1×
“Decreased appetite 75 (14) 7 (1) 133 (25) 5 (<1)”
Cited by
Items 701–800 of 1,016
Iisager, L., Ahrenfeldt, J., Donskov, F. N., Ljungberg, B., Bex, A., Lund, L. C., Lyskjær, I., & Fristrup, N. (2024) · BMC Cancer · doi:10.1186/s12885-024-11987-3 · Cited by 51
“…little is known about the immunomodulatory and biological effects of nivolumab combined with ipili-mumab, as well as the new treatment combination of TKI-IO therapy in mRCC, with the IO-IO therapy having no effect in 20% of patients with their best objective response being progressive disease [17].”
BackgroundSelf-citationPatel, J. S., Woo, Y., Draper, A., Jansen, C. S., Carlisle, J. W., Innominato, P. F., Lévi, F., Dhabaan, L., Master, V. A., Bilen, M. A., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008011 · Cited by 55
“17 18 We previously demonstrated that earlier time- of-day administration of immune checkpoint inhibitors (ICIs) is significantly associated with longer progression-free survival (PFS) and overall survival (OS) among patients with metastatic melanoma.”
BackgroundGuo, Y., Li, T., Gong, B., Hu, Y., Wang, S., Yang, L., & Zheng, C. (2024) · Advanced Science · doi:10.1002/advs.202408069 · Cited by 62
Zhang, J., Peng, Q., Fan, J., Liu, F., Chen, H., Bi, X., Yuan, S., Jiang, W., Pan, T. S., Li, K., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-06018-5 · Cited by 56
Huang, L., Zhu, H., & Shi, Y. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01734-x · Cited by 52
Fernandes, R., Jabbarizadeh, B., Rajeh, A., Hong, M. M. Y., Baines, K. J., Ernst, S., Winquist, E., Ali, A. S., Penny, S. L., Figueredo, R., et al. (2026) · Nature Medicine · doi:10.1038/s41591-025-04183-8 · Cited by 57
“1e ICIs have transformed the management of mRCC, yielding durable responses and improved survival in a subset of patients 1 .”
Hahn, A. W., Froerer, C., VanAlstine, S., Rathi, N., Bailey, E. B., Stenehjem, D. D., & Agarwal, N. (2018) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2018.05.001 · Cited by 46
Hájek, R., Lísa, M., Khalikova, M. A., Jirásko, R., Cífková, E., Študent, V., Vrána, D., Opálka, L., Vávrová, K., Matzenauer, M., et al. (2018) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-018-1263-8 · Cited by 47
Self-citationKrichevsky, A. M., & Uhlmann, E. J. (2019) · Neurotherapeutics · doi:10.1007/s13311-018-00702-3 · Cited by 50
Recurrent Pneumonitis in Patients with Melanoma Treated with Immune Checkpoint Inhibitors
Asher, N., Marom, E. M., Ben‐Betzalel, G., Baruch, E. N., Steinberg‐Silman, Y., Schachter, J., Shapira‐Frommer, R., & Markel, G. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0352 · Cited by 49
“ipilimumab and nivolumab was approved for the treatment of both metastatic melanoma and renal cell carcinoma (RCC), demonstrating improved response rate, progression free survival [9–11], and, for RCC, also overall survival over standard of care treatment [12].”
BackgroundCurrent Status and Future Directions of Immunotherapy in Renal Cell Carcinoma
Considine, B., & Hurwitz, M. E. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0779-1 · Cited by 48
Signorelli, D., Giannatempo, P., Grazia, G., Aiello, M. M., Bertolini, F., Mirabile, A., Buti, S., Vasile, E., Scotti, V., Pisapia, P., et al. (2019) · BioMed Research International · doi:10.1155/2019/9056417 · Cited by 51
Inamura, K., Amori, G., Yuasa, T., Yamamoto, S., Yonese, J., & Ishikawa, Y. (2019) · Cancer Management and Research · doi:10.2147/cmar.s209205 · Cited by 47
Tomita, Y., Kondo, T., Kimura, G., Inoue, T., Wakumoto, Y., Yao, M., Sugiyama, T., Oya, M., Fujii, Y., Obara, W., et al. (2019) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyz132 · Cited by 51
“The combination of nivolumab plus ipilimumab (NIVO+IPI) has been approved by the US Food and Drug Administration (3,4), the European Medicines Agency (5) and the Japanese Ministry of Health, Labor and Welfare (6) for the first-line treatment of patients with International Metastatic Renal Cell Carcinoma Database Conso…”
BackgroundMethodResultInfluentialSelf-citationRole of immune checkpoint inhibitors in the treatment of colorectal cancer: focus on nivolumab
Jacome, A. A. D. A., & Eng, C. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1680636 · Cited by 48
“of melanoma and renal-cell carcinoma [87,93], and, it is sugges-”
BackgroundLeighl, N. B., Redman, M. W., Rizvi, N. A., Hirsch, F. R., Mack, P. C., Schwartz, L. H., Wade, J. L., Irvin, W. J., Reddy, S., Crawford, J., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002973 · Cited by 49
Bispecific antibodies targeting CTLA-4: game-changer troopers in cancer immunotherapy
Farhangnia, P., Ghomi, S. M., Akbarpour, M., & Delbandi, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1155778 · Cited by 48
Targeted therapy for metastatic renal cell carcinoma
Hofmann, F., Marconi, L. S., Stewart, F. J., Lam, T. B. L., Bex, A., Canfield, S. E., & Ljungberg, B. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012796 · Cited by 46
Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors?
Nebot-Bral, L., Coutzac, C., Kannouche, P. L., & Chaput, N. (2018) · Bulletin du Cancer · doi:10.1016/j.bulcan.2018.08.007 · Cited by 52
Massari, F., Nunno, V. D., Gatto, L., Santoni, M., Schiavina, R., Cosmai, L., Brunocilla, E., Ardizzoni, A., & Porta, C. (2018) · Targeted Oncology · doi:10.1007/s11523-018-0601-2 · Cited by 46
Self-citationAutio, K. A., & Oft, M. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0760-z · Cited by 50
Pal, K., Madamsetty, V. S., Dutta, S. K., Wang, E., Angom, R. S., & Mukhopadhyay, D. (2019) · npj Precision Oncology · doi:10.1038/s41698-019-0105-2 · Cited by 55
“Lately, a combination of two immune checkpoint inhibitors, Nivolumab and Ipilimumab, eclipsed the efficacy of Sunitinib in a phase III trial and has been approved as the new standard of care treatment for intermediate- and poorrisk patients with previously untreated advanced RCC.(55) Moreover, the combination of Axiti…”
BackgroundBuonerba, C., Dolce, P., Iaccarino, S., Scafuri, L., Verde, A., Costabile, F., Pagliuca, M., Morra, R. P., Riccio, V., Ribera, D., et al. (2020) · Cancers · doi:10.3390/cancers12020408 · Cited by 47
“[15,16,24] Ipi + Nivo 425 60 8,2; (6,9–10) 8,4; (5,2–24) 0,77; (0,65–0,9) 0,38; (0,61–0,97) 35,6 31,2; (23-NE) 0,66; (0,54–0,8) 0,55; (0,33–0,9) 42 56,7 11 18,3”
BackgroundImpact of BMI on Survival Outcomes of Immunotherapy in Solid Tumors: A Systematic Review
Indini, A., Rijavec, E., Ghidini, M., Tomasello, G., Cattaneo, M., Barbin, F., Bareggi, C., Galassi, B., Gambini, D., & Grossi, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052628 · Cited by 50
Han, C., Meng, G.-X., Ding, Z., Dong, Z., Chen, Z., Hong, J., Yan, L., Liu, H., Tian, B., Yang, L.-S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.827788 · Cited by 50
NCCN Guidelines Updates: Management of Metastatic Kidney Cancer.
Jonasch, E. (2019) · PubMed · doi:10.6004/jnccn.2019.5008 · Cited by 46
Maurer, M. F., Lewis, K. E., Kuijper, J. L., Ardourel, D., Gudgeon, C. J., Chandrasekaran, S., Mudri, S., Kleist, K. N., Navas, C. L., Wolfson, M. F., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29286-5 · Cited by 48
Yuen, K. C. J., Samson, S. L., Bancos, I., Gosmanov, A. R., Jasim, S., Fecher, L. A., & Weber, J. S. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.04.010 · Cited by 46
Motzer, R. J., Schmidinger, M., Eto, M., Suárez, C., Figlin, R. A., Liu, Y., Perini, R. F., Zhang, Y., & Heng, D. Y. (2023) · Future Oncology · doi:10.2217/fon-2022-0802 · Cited by 55
Self-citationZhang, Z., Pan, Q., Lu, M., & Zhao, B. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102156 · Cited by 49
Cheng, L., Chen, L., Shi, Y., Gu, W., Ding, W., Zheng, X. W., Liu, Y., Jiang, J., & Zheng, Z. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01956-6 · Cited by 50
“6g, h, i and Supplementary Table S10) [236].”
BackgroundThe Role of Immune Checkpoint Inhibitors in Cancer Therapy: Mechanism and Therapeutic Advances
Chen, H., Yang, H., Guo, L., & Sun, Q. (2025) · MedComm · doi:10.1002/mco2.70412 · Cited by 67
Response to PD1 inhibition in conventional chondrosarcoma
Wagner, M. J., Ricciotti, R. W., Mantilla, J. G., Loggers, E. T., Pollack, S. M., & Cranmer, L. D. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0413-z · Cited by 50
Onesti, C. E., Frères, P., & Jérusalem, G. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.12.47 · Cited by 46
“Further clinical trials are currently ongoing, testing adjuvant immunotherapy in RCC (clinicaltrials. gov: NCT03288532), in esophageal or gastro-esophageal junction cancer (NCT02743494), in gastric cancer (NCT03443856), in head and neck cancer (NCT03406247), in hepatocarcinoma (NCT03630640) and in urothelial cancer (N…”
BackgroundBrain Metastasis From Renal-Cell Carcinoma: An Institutional Study
Suarez‐Sarmiento, A., Nguyen, K. A., Syed, J. S., Nolte, A., Ghabili, K., Cheng, M., Liu, S. T., Chiang, V., Kluger, H. M., Hurwitz, M. E., et al. (2019) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.08.006 · Cited by 45
McGregor, B. A., Gordon, M. S., Flippot, R., Agarwal, N., George, S., Quinn, D. I., Rogalski, M., Hawthorne, T. R., Keler, T., & Choueiri, T. K. (2020) · Investigational New Drugs · doi:10.1007/s10637-020-00945-y · Cited by 46
Self-citationPimentel, V. O., Marcus, D., van der Wiel, A. M.-M. A., Lieuwes, N. G., Biemans, R., Lieverse, R. I. Y., Neri, D., Theys, J., Yaromina, A., Dubois, L. J., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001764 · Cited by 49
Klümper, N., Ralser, D. J., Zarbl, R., Schlack, K., Schrader, A. J., Rehlinghaus, M., Hoffmann, M. J., Niegisch, G., Uhlig, A., Trojan, L., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002949 · Cited by 47
Targeted therapy for metastatic renal cell carcinoma
Hofmann, F., Hwang, E. C., Lam, T. B. L., Bex, A., Yuan, Y., Marconi, L. S., & Ljungberg, B. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012796.pub2 · Cited by 52
Frailty and checkpoint inhibitor toxicity in older patients with melanoma
Bruijnen, C. P., Koldenhof, J. J., Verheijden, R. J., van den Bos, F., Emmelot‐Vonk, M. H., Witteveen, P. O., & Suijkerbuijk, K. P. M. (2022) · Cancer · doi:10.1002/cncr.34230 · Cited by 52
“In addition to having demonstrated superior efficacy, often with durable clinical benefits in many tumor types, the safety profile of ICI therapy generally compares favorably to that of chemotherapy and targeted therapy.(3,7) Immune- related adverse events (irAEs), the immunemediated toxicities that occur during ICI t…”
Background(2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0422-y · Cited by 44
Shaikh, F. Y., White, J. R., Gills, J. J., Hakozaki, T., Richard, C., Routy, B., Okuma, Y., Usyk, M., Pandey, A., Weber, J. S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4834 · Cited by 44
“Between-study heterogeneity analysis included estimates of I(2) (% of variation estimated as true study-tostudy heterogeneity), t(2) (the random effects between study variance estimate), and Cochran Q test P value (39, 40).”
BackgroundKamli, H. M., Li, L., & Gobe, G. C. (2019) · Ochsner Journal · doi:10.31486/toj.18.0015 · Cited by 53
Cooley, L. S., Rudewicz, J., Souleyreau, W., Emanuelli, A., Álvarez-Arenas, A., Clarke, K., Falciani, F., Dufies, M., Lambrechts, D., Modave, E., et al. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01416-5 · Cited by 44
Self-citationRizzo, M., Varnier, L., Pezzicoli, G., Pirovano, M., Cosmai, L., & Porta, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.990568 · Cited by 53
“The double ICI combination ipilimumab plus nivolumab has been approved as first-line treatment in IMDC intermediate and poor-risk patients (1, 10, 11).”
BackgroundSelf-citationSantoni, M., Massari, F., Myint, Z. W., Iacovelli, R., Pichler, M., Basso, U., Kopecký, J., Kucharz, J., Buti, S., Rizzo, M., et al. (2023) · Targeted Oncology · doi:10.1007/s11523-023-00978-2 · Cited by 48
Self-citationGrünwald, V., Powles, T. B., Eto, M., Kopyltsov, E., Rha, S. Y., Porta, C., Motzer, R. J., Hutson, T. E., Méndez-Vidal, M. J., Hong, S., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1223282 · Cited by 44
“Nivolumab plus ipilimumab was favored over sunitinib for OS, for most subgroups, including patients who did not have bone metastases, patients irrespective of liver metastases, patients with lung metastases, and patients regardless of prior nephrectomy (20).”
BackgroundSelf-citationFrentzas, S., Gan, H. K., Cosman, R., Coward, J. I. G., Tran, B., Millward, M., Zhou, Y., Wang, W., Xia, D., Wang, Z. M., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101242 · Cited by 53
Ghoreifi, A., Vaishampayan, U. N., Yin, M., Psutka, S. P., & Djaladat, H. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.5269 · Cited by 44
Zhang, Y., Huang, Y., Yu, D., Xu, M., Hu, H., Zhang, Q., Cai, M., Geng, X., Zhang, H., Xia, J., et al. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.08.004 · Cited by 50
“PD-1/PD-L1 immune checkpoint inhibitor therapy can exert a significant therapeutic effect by restoring the host’s antitumor immunity and has revolutionized the treatment of advanced solid tumors 42,43 .”
Verbiest, A., Renders, I., Caruso, S., Couchy, G., Job, S., Laenen, A., Verkarre, V., Rioux-Leclercq, N. C., Schöffski, P., Vano, Y. A., et al. (2019) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.05.009 · Cited by 48
Programmed Cell Death-1/Ligand-1 PET Imaging
Verhoeff, S. R., van den Heuvel, M. M., van Herpen, C. M. L., Piet, B., Aarntzen, E. H. J. G., & Heskamp, S. (2019) · PET Clinics · doi:10.1016/j.cpet.2019.08.008 · Cited by 45
T-cell-based breast cancer immunotherapy
Pilipow, K., Darwich, A., & Losurdo, A. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.05.019 · Cited by 45
McIntosh, A. G., Umbreit, E. C., Holland, L. C., Gu, C., Tannir, N. M., Matin, S. F., Karam, J. A., Culp, S. H., & Wood, C. G. (2020) · Cancer · doi:10.1002/cncr.32991 · Cited by 44
Self-citationUdayakumar, D., Zhang, Z., Xi, Y., Dwivedi, D. K., Fulkerson, M., Haldeman, S., McKenzie, T., Yousuf, Q., Joyce, A., Hajibeigi, A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0706 · Cited by 68
“Yet, a percentage of patients, in particular those with low-risk disease, may experience superior oncologic outcomes with TKI treatment compared to IO (11).”
BackgroundWang, Y., Yang, T., Li, Q., Zheng, Z., Liao, L., Cen, J., Chen, W., Luo, J., Xu, Y., Zhou, M., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-024-02122-8 · Cited by 56
Labadie, B. W., Liu, P., Bao, R., Crist, M., Fernandes, R., Ferreira, L., Graupner, S., Poklepovic, A. S., Durán, I., Vareki, S. M., et al. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-02144-7 · Cited by 45
“In previously untreated metastatic ccRCC, anti-PD1/L1 antibodies combined with VEGFR2 TKI is emerging [7, 8].”
Zhou, Y., Zhang, Y., Guo, G., Cai, X., Yu, H., Cai, Y., Zhang, B., Hong, S., & Zhang, L. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.14 · Cited by 43
lncRNA and Mechanisms of Drug Resistance in Cancers of the Genitourinary System
Barth, D. A., Juráček, J., Slabý, O., Pichler, M., & Calin, G. A. (2020) · Cancers · doi:10.3390/cancers12082148 · Cited by 47
“Nonetheless, the introduction of immune checkpoint inhibitors such as nivolumab, pembrolizumab and combinations with antiangiogenetic agents in the treatment of ccRCC drastically improved the outcome of metastatic RCC [5,56].”
BackgroundHu, H., She, L., Liao, M., Shi, Y., Yao, L., Ding, D., Zhu, Y., Zeng, S., Carbone, D. P., & Huang, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01649 · Cited by 44
Thouvenin, L., Olivier, T., Banna, G. L., Addeo, A., & Friedlaender, A. (2021) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986211004745 · Cited by 45
Biomarkers for Renal Cell Carcinoma Recurrence: State of the Art
Marchioni, M., Rivas, J. G., Autrán, A., Socarrás, M. E. R., Albisinni, S., Ferro, M., Schips, L., Scarpa, R. M., Papalia, R., & Esperto, F. (2021) · Current Urology Reports · doi:10.1007/s11934-021-01050-0 · Cited by 43
Anti-angiogenesis Revisited: Combination with Immunotherapy in Solid Tumors
Chambers, A., Kundranda, M. N., Rao, S. K., Mahmoud, F. A., & Niu, J. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01099-7 · Cited by 48
Tucker, M. D., Brown, L. C., Chen, Y., Kao, C., Hirshman, N. A., Kinsey, E. N., Ancell, K. K., Beckermann, K. E., Davis, N. B., McAlister, R. K., et al. (2021) · Biomarker Research · doi:10.1186/s40364-021-00334-4 · Cited by 44
Self-citationLombardi, P., Filetti, M., Falcone, R., Bidino, R. D., Iacovelli, R., Ciccarese, C., Bria, E., Tortora, G., Scambia, G., & Daniele, G. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102377 · Cited by 46
Bhatlapenumarthi, V., Patwari, A., & Harb, A. J. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03610-w · Cited by 45
“The incidence of irAEs is higher with combination therapy than with monotherapy alone (Motzer et al. 2018; Hellmann et al. 2018; Wolchok et al. 2017).”
BackgroundRebuzzi, S. E., Signori, A., Buti, S., Banna, G. L., Murianni, V., Damassi, A., Maruzzo, M., Giannarelli, D., Tortora, G., Galli, L., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100634 · Cited by 42
Self-citationThe evolving landscape of PCSK9 inhibition in cancer
Oza, P. P., & Kashfi, K. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175721 · Cited by 44
Lin, H., Fu, L., Li, P., Zhu, J., Xu, Q., Wang, Y., Mumin, M. A., Zhou, X., Chen, Y., Shu, G., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04161-z · Cited by 49
“Antibodies against PD-1, including nivolumab and pembrolizumab, serve as a useful treatment of metastatic RCC [3, 4].”
BackgroundDynamics of resistance to immunotherapy and TKI in patients with advanced renal cell carcinoma
Santoni, M., Mollica, V., Rizzo, A., & Massari, F. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102881 · Cited by 47
An Update on Predictive Biomarkers in Metastatic Renal Cell Carcinoma
Dudani, S., Savard, M.-F., & Heng, D. Y. C. (2019) · European Urology Focus · doi:10.1016/j.euf.2019.04.004 · Cited by 44
Martini, D. J., Liu, Y., Shabto, J. M., Carthon, B. C., Hitron, E., Russler, G. A., Caulfield, S. E., Kissick, H. T., Harris, W. B., Küçük, Ö., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0578 · Cited by 42
Dudek, A. Z., Liu, L. C., Gupta, S., Logan, T. F., Singer, E. A., Joshi, M., Zakharia, Y., Lang, J. M., Schwarz, J. K., Al-Janadi, A., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02394 · Cited by 46
Determinants of Resistance to Checkpoint Inhibitors
Tran, L. L., & Theodorescu, D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051594 · Cited by 47
Suzuki, S., Ogawa, T., Sano, R., Takahara, T., Inukai, D., Satou, A., Tsuchida, H., Yoshikawa, K., Ueda, R., & Tsuzuki, T. (2020) · Cancer Science · doi:10.1111/cas.14422 · Cited by 46
Shi, X., Song, H., Wang, C., Zhang, C., Huang, P., Kong, D., Zhang, J., & Wang, W. (2020) · Chemical Engineering Journal · doi:10.1016/j.cej.2020.125854 · Cited by 43
Epaillard, N., Simonaggio, A., Elaidi, R., AZZOUZ, F., Braychenko, E., Thibault, C., Sun, C., Moreira, M., Oudard, S. M., & Vano, Y. A. (2020) · Bulletin du Cancer · doi:10.1016/s0007-4551(20)30283-6 · Cited by 46
Landre, T., Guetz, G. D., Chouahnia, K., Fossey-Diaz, V., & Culine, S. (2020) · Drugs & Aging · doi:10.1007/s40266-020-00788-5 · Cited by 43
Renal cell carcinoma (RCC): fatter is better? A review on the role of obesity in RCC
Turco, F., Tucci, M., Stefano, R. F. D., Samuelly, A., Bungaro, M., Audisio, M., Pisano, C., Maïo, M. D., Scagliotti, G. V., & Buttigliero, C. (2021) · Endocrine Related Cancer · doi:10.1530/erc-20-0457 · Cited by 50
Immune checkpoint-targeted antibodies: a room for dose and schedule optimization?
Maritaz, C., Broutin, S., Chaput, N., Marabelle, A., & Paci, A. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01182-3 · Cited by 52
“These observations guided the choice of the dose of 1 mg/kg for ipilimumab in the pivotal Phase III CheckMate 214 trial [47].”
BackgroundA Tale of Two Checkpoints: ATR Inhibition and PD-(L)1 Blockade
Ngoi, N. Y. L., Peng, G., & Yap, T. A. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-042320-025136 · Cited by 46
Lo, J. W., Cozzetto, D., Alexander, J. L., Danckert, N. P., Madgwick, M., Knox, N., Sieh, J. Y. X., Olbei, M. L., Liu, Z., Ibraheim, H., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41798-2 · Cited by 49
“Immune checkpoint inhibitors (CPIs) are highly effective immu-notherapeuticsthathavetransformedtreatmentparadigmsforseveral cancers 1 – 6 .”
BackgroundBeckermann, K. E., Patnaik, A., Winer, I. S., Tan, W. W., Bashir, B., Kyriakopoulos, C. E., Sweis, R. F., Chamberlain, M. C., & Rini, B. I. (2024) · Investigational New Drugs · doi:10.1007/s10637-024-01419-1 · Cited by 42
Self-citationTargeting the PD-1/PD-L1 Signaling Pathway for Cancer Therapy: Focus on Biomarkers
Strati, A. D., Adamopoulos, C., Kotsantis, I., Psyrri, A. K., Lianidou, E. S., & Papavassiliou, A. G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031235 · Cited by 51
“Specifically, longer OS and higher objective response rates were observed in intermediate-and low-risk patients across all PD-L1 expression levels, although the magnitude of benefit was higher in the population with PD-L1 expression of 1% or greater [165].”
Ayers, M., Nebozhyn, M., Cristescu, R., McClanahan, T. K., Perini, R. F., Rubin, E. H., Cheng, J. D., Kaufman, D. R., & Loboda, A. P. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1316 · Cited by 43
“In a phase Ib, nonrandomized dose-finding and dose-expansion trial, the combination of pembrolizumab and axitinib conferred an ORR of 73% in a cohort of 52 patients with previously untreated, advanced RCC who were unselected for PD-L1 expression (KEYNOTE-035, NCT02133742; ref.”
BackgroundInfluentialImmunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma
Labriola, M., Batich, K. A., Zhu, J., McNamara, M. A., Harrison, M. R., Armstrong, A. J., George, D. J., & Zhang, T. (2019) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.01.017 · Cited by 42
Weingarten, N., Kruser, T. J., & Bloch, O. G. (2019) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2019.02.010 · Cited by 41
The Future of Perioperative Therapy in Advanced Renal Cell Carcinoma: How Can We Prosper?
Patel, H. D., Puligandla, M., Shuch, B. M., Leibovich, B. C., Kapoor, A., Master, V. A., Drake, C. G., Heng, D. Y., Lara, P. N., Choueiri, T. K., et al. (2019) · Future Oncology · doi:10.2217/fon-2018-0951 · Cited by 44
Self-citationClinical Studies Applying Cytokine-Induced Killer Cells for the Treatment of Renal Cell Carcinoma
Zhang, Y., Ellinger, J., Ritter, M., & Schmidt‐Wolf, I. G. H. (2020) · Cancers · doi:10.3390/cancers12092471 · Cited by 41
“A significantly higher overall survival (OS) and objective response rates were achieved with nivolumab plus ipilimumab than with sunitinib [8].”
BackgroundDufies, M., Verbiest, A., Cooley, L. S., Ndiaye, P. D., Viotti, J., He, X., Nottet, N., Souleyreau, W., Hagege, A., Torrino, S., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-01653-w · Cited by 46
Self-citationRelecom, A., Merhi, M., Inchakalody, V. P., Shahab Uddin, M. S., Rinchai, D., Bedognetti, D., & Dermime, S. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01872-3 · Cited by 44
“Despite being associated with an increased incidence of irAE, the therapeutic benefit conferred by this combination led to the Food and Drug Administration (FDA) to grant its further approval in intermediate and poor risk advanced renal cell carcinoma, metastatic NSCLC with > 1 % PD-L1 expression as well as in hepatoc…”
BackgroundBasso, U., Facchinetti, A., Rossi, E. M. C., Maruzzo, M., Conteduca, V., Aieta, M., Massari, F., Fraccon, A. P., Mucciarini, C., Sava, T., et al. (2021) · The Oncologist · doi:10.1002/onco.13842 · Cited by 41
Serzan, M. T., & Atkins, M. B. (2021) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2021.76 · Cited by 45
New approaches to first-line treatment of advanced renal cell carcinoma
George, D. J., Lee, C., & Heng, D. Y. C. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211034708 · Cited by 43
Ciccarese, C., Iacovelli, R., Porta, C., Procopio, G., Bria, E., Astore, S., Cannella, M. A., & Tortora, G. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102295 · Cited by 43
Self-citationThe Immunotherapy and Immunosuppressive Signaling in Therapy-Resistant Prostate Cancer
Xu, P., Wasielewski, L. J., Yang, J. C., Cai, D., Evans, C. P., Murphy, W. J., & Liu, C. (2022) · Biomedicines · doi:10.3390/biomedicines10081778 · Cited by 46
“, melanoma [19], kidney cancer [20], and non-small-cell lung cancer [21]) are often referred to as having “hot tumors” because of the considerable reliance they have on immune checkpoints for propagation.”
BackgroundChoueiri, T. K., Kluger, H. M., George, S., Tykodi, S. S., Kuzel, T. M., Perets, R., Nair, S., Procopio, G., Carducci, M. A., Castonguay, V., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005780 · Cited by 41
Self-citationLatest Advances in the Use of Therapeutic Focused Ultrasound in the Treatment of Pancreatic Cancer
Mouratidis, P., & ter Haar, G. (2022) · Cancers · doi:10.3390/cancers14030638 · Cited by 46
State of the Art: Multidisciplinary Management of Oligometastatic Renal Cell Carcinoma
Dason, S., Lacuna, K. P., Hannan, R., Singer, E. A., & Runcie, K. D. (2023) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_390038 · Cited by 41
Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US
Kerekes, D. M., Frey, A. E., Prsic, E. H., Tran, T. T. T., Clune, J. E., Sznol, M., Kluger, H. M., Forman, H. P., Becher, R. D., Olino, K. L., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2023.6025 · Cited by 42
Metadata
- Authors
- Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., Powles, T., Donskov, F., Neiman, V., Kollmannsberger, C. K., Salman, P., Gurney, H., Hawkins, R., Ravaud, A., Grimm, M.-O., Bracarda, S., Barrios, C. H., Tomita, Y., Castellano, D., Rini, B. I., Chen, A. C., Mekan, S., McHenry, M. B., Wind-Rotolo, M., Doan, J., Sharma, P., Hammers, H. J., & Escudier, B.
- Affiliations
- Brigham and Women's Hospital (US)
- From Memorial Sloan Kettering Cancer Center, New York (R.J.M.), and Roswell Park Cancer Institute, Buffalo (S.G.) — both in New York; University of Texas M.D. Anderson Cancer Center, Houston (N.M.T., P. Sharma); Beth Israel Deaconess Medical Center, Dana–Farber/Harvard Cancer Center (D.F.M.), and Dana–Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School (T.K.C.), Boston; Centro Internacional de Estudios Clínicos (O.A.F.) and Fundación Arturo López Pérez (P. Salman),...
- ORCID
- Motzer, Robert J.
- Tannir, Nizar M.
- McDermott, David F.
- Melichar, Bohuslav
- Choueiri, Toni K.
- Plimack, Elizabeth R.
- Barthélémy, Philippe
- Porta, Camillo
- George, Saby
- Powles, Thomas
- Donskov, Frede
- Kollmannsberger, Christian K.
- Salman, Pamela
- Gurney, Howard
- Ravaud, Alain
- Grimm, Marc-Oliver
- Barrios, Carlos H.
- Tomita, Yoshihiko
- Castellano, Daniel
- Rini, Brian I.
- Mekan, Sabeen
- McHenry, M. Brent
- Sharma, Padmanee
- Hammers, Hans J.
- Escudier, Bernard
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-04-05
- Volume
- 378
- Issue
- 14
- Pages
- 1277-1290
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5972549
- OpenAlex
- W2792937256
- Cited by
- 4,656
- References
- 31
- Citations by year
- 2026: 305 · 2025: 416 · 2024: 510 · 2023: 601 · 2022: 656 · 2021: 708 · 2020: 684 · 2019: 562 · 2018: 209
- FWCI
- 408.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion, other-oa)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion, other-oa)
- Tampere University Institutional Repository (Tampere University) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Ono Pharmaceutical Company Limited
- Topics
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Keywords
- nivolumab plus ipilimumab, sunitinib, advanced renal cell carcinoma, clear cell renal cell carcinoma, immune checkpoint inhibitors, PD-1 inhibitors, CTLA-4 inhibitors, combination immunotherapy, overall survival, objective response rate, progression-free survival, treatment-related adverse events, immune-related adverse events, first-line therapy
- MeSH terms
- Antineoplastic Agents, Immunological, Ipilimumab, Sunitinib, Nivolumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Humans, Indoles, Kidney Neoplasms, Male, Middle Aged, Pyrroles, Quality of Life, Risk, Survival Rate, Survival Analysis, Disease-Free Survival
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.